|
V51139
|
Blontuvetmab (AT-004; VT-007) |
1608112-78-2 |
Blontuvetmab (AT 004) is a canine CD20 monoclonal antibody (mAb). |
|
V51118
|
Denintuzumab (hBU-12) |
1630074-14-4 |
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody (mAb). |
|
V51134
|
Divozilimab (BCD-132) |
2254061-60-2 |
Divozilimab (BCD-132) is a humanized monoclonal antibody (mAb) against CD20 (CD20). |
|
V79330
|
Eramkafusp Alfa |
|
Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1. |
|
V51138
|
Imvotamab (IGM-2323) |
2573121-53-4 |
anti-CD20/3 bispecific antibody (bsAb) |
|
V51136
|
Ocaratuzumab (AME-133v) |
1169956-08-4 |
Ocaratuzumab (AME 133v), an Fc-engineered antibody, is a humanized IgG1 anti-CD20 monoclonal antibody (mAb) with a Kd of ~100 pM. |
|
V74761
|
Ocrelizumab (Omelizumab; Ocrevus) |
637334-45-3 |
Omelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. |
|
V51135
|
Plamotamab (XmAb-13676) |
2138442-31-4 |
Plamotamab (XmAb-13676) is a human bisAb (bsAb) that binds CD3 and CD20. |
|
V51132
|
Ripertamab (SCT-400) |
2249927-04-4 |
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ tumor. |
|
V51130
|
Tositumomab |
192391-48-3 |
Tositumomab is a mouse IgG2a lambda monoclonal antibody (mAb) targeting the CD20 antigen, which is present on the surface of normal and malignant B lymphocytes. |
|
V51133
|
Ublituximab (TG-1101; LFB-R603; TGTX-1101) |
1174014-05-1 |
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation type 1 chimeric monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen. |
|
V51137
|
Zuberitamab (HS-006) |
2251143-19-6 |
Zuberitamab (HS006) is a monoclonal antibody (mAb) targeting CD20 for use in cancer-related research like diffuse large B-cell lymphoma. |